

3D-printed electrospinning setup for the preparation of loratadine nanofibers with enhanced physicochemical properties

Rita Ambrus^a, Areen Alshweiat^a, Ildikó Csóka^a, George Ovari^b, Ammar Esmail^b, Norbert Radacsi^b

^aInstitute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Interdisciplinary Excellence Centre, Eötvös u. 6, H-6720 Szeged, Hungary

^bThe School of Engineering, Institute for Materials and Processes, The University of Edinburgh, Robert Stevenson Road, Edinburgh, EH9 3FB, UK

*Correspondence to Norbert Radacsi

The School of Engineering, Institute for Materials and Processes, The University of Edinburgh, Robert Stevenson Road, Edinburgh, EH9 3FB, UK

Tel: +44 131 651 3571

E-mail: n.radacsi@ed.ac.uk

25

26

27 **ABSTRACT**

28 This study investigates the effects of drug-loaded nanofibers on the solubility of the poorly
29 water-soluble drug, **loratadine**. Amorphous morphologies of electrospun loratadine nanofibers
30 were prepared using a 3D-printed electrospinning setup. Polyvinylpyrrolidone was used as a
31 carrier in the solvent preparation method. The prepared nanofibers were characterized by
32 scanning electron microscopy, differential scanning calorimetry, X-ray diffraction analysis,
33 Fourier transform infrared spectroscopy, solubility and in vitro dissolution studies with kinetic
34 behavior evaluation. The scanning electron microscope images showed smooth nanofiber
35 surfaces with a mean diameter of 372 nm. Moreover, both differential scanning calorimetry
36 and X-ray diffraction analysis confirmed the amorphous state of the prepared nanofibers. FT-
37 IR results suggested that loratadine lost its original crystal structure by hydrogen bonding
38 interactions. The fabricated nanofibrous drug samples demonstrated a remarkable 26-fold
39 increase in solubility when compared to the pure drug in phosphate buffer at pH 7.4.
40 Furthermore, dissolution studies showed that 66% of the drug from the nanofibrous mat was
41 released in the first 10 min, which is significantly higher than the maximum of 4% drug
42 release of the reference samples within the same time. Thus, Loratadine nanofibers can be
43 considered as an alternative dosage form with improved physicochemical properties.

44

45 **Keywords:** Electrospinning, 3D printing, Nanofibers, Loratadine, Physicochemical analysis

46

47 **1. INTRODUCTION**

48 Loratadine (LOR) is a second-generation anti-histamine (H₁) agent. It is frequently prescribed
49 to treat allergic disorders without a central nervous system depressant effects (Simons, 2002).

50 LOR belongs to class II of the biopharmaceutical classification system that exhibits a poor
51 water solubility ($0.00303 \text{ mg mL}^{-1}$) and high permeability ($\log P$ of 5) (Dagenais et al., 2009).
52 From the chemical point of view, LOR contains pyridine nitrogen atom that is responsible for
53 its pH-dependent solubility (Han et al., 2004). Its pKa value at 25 °C has been reported as
54 4.85–6.00 (Dagenais et al., 2009; Han et al., 2004; Omar et al., 2007). Related to the
55 properties mentioned above, LOR shows low and variable bioavailability (Arya et al., 2012).
56 Many possibilities have been applied to enhance the dissolution and solubility of LOR, which
57 includes solid dispersion, inclusion with β -cyclodextrin derivatives, micellar solubilization
58 and self-microemulsifying drug systems (Frizon et al., 2013; Li et al., 2015; Nacsá et al.,
59 2009, 2008).

60 In recent years, many efforts have been devoted to utilizing nanoparticle design for increasing
61 the bioavailability of drugs. Preparation of LOR nanoparticles has been shown to enhance its
62 dissolution and solubility (Alshweiat et al., 2018; Rodriguez Amado et al., 2017). The use of
63 nanoparticles to produce LOR with increased hydrophilic properties shows promise and has
64 opened the scope for new methods of preparation and administrations (Akhgari et al., 2016).
65 Nanofibers, due to their architecture, are considered to be a sophisticated solution to the
66 current inconveniences of drug delivery (Li et al., 2015). Drugs based on nanofibers show
67 faster dissolution kinetics than their micron-sized counterparts, as nanofibers have a
68 significantly higher surface area to volume ratio (Jiang et al., 2004).

69 Among different method of preparation, electrospinning is considered as the most efficient
70 process in nanofiber production. This process has been recognized as simple and versatile to
71 produce nanofibers with low cost (Huang et al., 2003). Radacsi et al. (Radacsi et al., 2018)
72 reported the benefits of electrospinning on scaling up to high yield. This feature makes
73 electrospinning attractive for the industry over the electrospray **technique**. Both methods **are**

74 based on electrohydrodynamic atomization and have been demonstrated to improve the
75 physicochemical properties of drug particles (Ambrus et al., 2013; Radacsi et al., 2019).

76 The poor water solubility of the active pharmaceutical ingredients (APIs) and candidates is
77 one of the major challenges of the pharmaceutical industry (Craig, 2002). The delivery of
78 these agents is associated with poor bioavailability (Amidon et al., 1995). As a novel drug
79 manufacturing method, electrospinning is mainly focused on enhancing the dissolution of
80 poorly water-soluble drugs. The enhanced dissolution of drugs in the nanofibers are related to
81 presence of the amorphous state, high specific surface area, increased wettability and
82 solubility, and lower precipitation (Nagy et al., 2012). This offers alternative drug delivery
83 methods, e.g. the electrospun drug films can be used for transdermal delivery, or it can
84 dissolve in the oral cavity (e.g. sublingual or buccal administration), which can be
85 advantageous for patients that cannot swallow (Shahriar et al., 2019). Furthermore, the
86 advanced bioavailability also reduces the side-effects of the drugs (Badawy et al., 1996).

87 Recently, academic and industrial efforts have concentrated on enhancing the dissolution of
88 the poorly water-soluble pharmaceutical agents by electrospinning technology. The
89 fabrication of itraconazole nanofibers using the co-polymer PVPVA64 as a carrier was done
90 by novel high-speed electrospinning method (Nagy et al., 2015). The produced amorphous
91 nanofibers showed rapid dissolution, 90% of the drug was dissolved within 10 min. The high-
92 speed electrospinning method has a significantly higher production rate than the conventional
93 electrospinning techniques, making it attractive for industrial pharmaceutical manufacturing.

94 In another study, electrospinning of itraconazole was performed with
95 hydroxypropylmethylcellulose as a carrier polymer (Verreck et al., 2003). The authors
96 highlighted the amorphous structure and the rapid and complete dissolution of the API,
97 itraconazole, from the prepared nanofibers.

98 Electrospinning has been utilized in poorly water-soluble analgesics. Ketoprofen showed a
99 significant dissolution from the prepared nanofibers with PVP K30 as a drug carrier and
100 filament-forming a polymer. The complete drug release was achieved within just 30 min.
101 However, the pure drug showed approximately 5% release after 2 h (Yu et al., 2010).
102 Moreover, niflumic acid loaded nanofibers into PVP (MW = 1,300,000) were incorporated
103 into capsules. The formulations showed a drug release of 69-91% after 15 min (Radacsi et al.,
104 2019). The high drug release from nanofibers was also achieved in acetaminophen. Yu et al
105 (Yu et al., 2010) found that 93.8% of poorly water-soluble acetaminophen was released in the
106 first 2 min from the PVP (Mw=360,000) drug-loaded nanofibers. Furthermore, ibuprofen has
107 been fabricated into nanofibers (Potrč et al., 2015). The nanofibers released 100% of the
108 ibuprofen in 4 h.

109 To prepare nanofibers of the poorly water-soluble plant sterol. Paaver and co-workers (Paaver
110 et al., 2016) fabricated β -sitosterol loaded chitosan nanofibers. The prepared nanofibers
111 exhibited freely water-soluble properties with a very short lag-time in releasing the β -
112 sitosterol. In a study by Li et al (Li et al., 2013), rapid and improved dissolution rates have
113 been achieved for caffeine and riboflavin nanofibers, using polyvinyl alcohol polymer as
114 filament-forming polymer and drug carrier. The nanofibers showed 100% and 40% release of
115 caffeine and riboflavin, respectively within 60 s.

116 In comparison to the conventional processes of solid dispersion fabrication, electrospinning
117 can produce nanofibers with enhanced dissolution compared to film casting (Potrč et al.,
118 2015) freeze-drying, vacuum drying, and heating drying (Yu et al., 2010).

119 Many studies discussed the effects of the material and process parameters of electrospinning
120 on the release of poorly water-soluble drugs from the nanofibers. These parameters include;
121 drug characteristics (Potrč et al., 2015), polymer type (Baskakova et al., 2016), drug and
122 polymer ratios (Brewster et al., 2004), solvents type and ratios (Paaver et al., 2016), in

123 addition to the electrospinning parameters of voltage (Verreck et al., 2003), and the distance
124 between the collector and the spinneret (Radacsi et al., 2019).

125 The material properties affect the properties of the solutions, such as viscosity and surface
126 tension thus morphology and size of the electrospun nanofibers (Fong et al., 1999). In general,
127 concentration is a critical factor determining the solution viscosity, whereas polymer and
128 solvent affect the value of the surface tension (Yang et al., 2004). Moreover, adjusting the
129 process parameters has significant effects on controlling the final structure of the electrospun
130 fibers (Ryu et al., 2003).

131 Polyvinylpyrrolidone (PVP) is a widely used polymer for preparing electrospun fibers. It
132 shows low toxicity, high biocompatibility and excellent solubility in most organic solvents
133 (Chuangchote et al., 2009). Furthermore, PVP with the M_w 1,300,000 $g\ mol^{-1}$ has been the
134 most thoroughly investigated in reported studies related to electrospinning with PVP (Li and
135 Xia, 2003; Nuansing et al., 2006).

136 In the present study, a low-cost 3D-printed electrospinning setup is investigated as a new
137 formulation method for the fabrication of nanostructured LOR. From the production point of
138 view, this study considered the first application of a setup prepared by fused deposition
139 modelling printing method with 3D-printed components (Huang and Radacsi, 2019).
140 Concerning the pharmaceutical goal, this study aimed to produce nanofiber with enhanced
141 dissolution and high drug loading of the poorly water-soluble LOR. These properties enable
142 the incorporation of the nanofibers into different dosage form such as oral, buccal, topical,
143 and transdermal with improved bioavailability. The size and morphology of the produced
144 LOR-PVP nanofibers were characterized by scanning electron microscopy. The structure of
145 the products was investigated using differential scanning calorimetry, X-ray powder
146 diffraction and Fourier transform infrared. The solubility and *in vitro* release of the selected

147 product was studied in a phosphate buffer solution at pH 7.4 and was compared with the
148 corresponding physical mixture and a prepared reference sample.

149

150 **2. Experimental**

151 **2.1 Materials**


152 Loratadine (LOR) was purchased from Teva Ltd. (Budapest, Hungary). Polyvinylpyrrolidone
153 (PVP; M_w 1,300,000 g mol⁻¹) was purchased from Alfa Aesar, UK. 99.99% purity ethanol
154 was obtained from Fisher Scientific, UK.

155

156 **2.2. Solution preparation and electrospinning**

157 LOR: PVP at 1:1 ratio was used to prepare the electrospinning samples containing PVP as a
158 carrier and ethanol as a solvent system. 0.77 g LOR was mixed with 0.77 g PVP, and this
159 powder mixture was dissolved in 50 mL ethanol. The electrical conductivity of the solution
160 was 2 $\mu\text{S cm}^{-1}$. This solution was sucked into a 60 mL syringe (BD plastics). The nanofibers
161 were produced in a 3D-printed electrospinning setup (Figure 1). The details of the 3D printing
162 process and the files of the electrospinning setup can be found in another work (Huang and
163 Radacsi, 2019). A 20G needle was applied at the tip of the syringe, and it was placed into the
164 syringe pump (Cole-Parmer, USA). The LOR solution was injected into the 3D-printed
165 chamber through a Teflon tube using the automatic pump with a pumping speed of
166 15 $\mu\text{L min}^{-1}$. The Teflon tube (inner diameter 0.8 mm) was connected to a blunt 20G needle
167 that was placed inside the 3D-printed setup and was covered by a safety cap to prevent
168 electric shock. The blunt nozzle was charged by a +35 kV DC high-voltage power supply
169 (Information Unlimited, Amherst, USA) at its maximum voltage. The working distance (WD)
170 between the spinneret and the fiber collector was set to either 65 or 95 mm (95 mm was the
171 maximum distance possible in the setup without using extension parts). The fibers were

172 collected on an 80 mm wide grounded stainless steel drum, which was rotating with a speed
173 of 100 rpm. A constant stream of air (5.2 ms^{-1}) was supplied into the chamber opposing the
174 direction of the electrospun fibers, in order to increase the evaporation rate of the solvent from
175 the electrospun jet and the fibers as they travelled across the chamber. Two different working
176 distances between the injection nozzle and the collection drum were tested in the experiments,
177 and all the other parameters were fixed. The experiments were performed at room temperature
178 at the relative humidity of 42-49%. Each run lasted for 15 minutes.



179
180 **Figure 1.** Schematic illustration of the 3D-printed modular electrospinning setup.

181 182 **2.3 Preparation of the reference samples**

183 The reference samples, physical mixture (PM) and the solvent evaporated sample (SE), were
184 prepared by two different methods to control the effect of polymer and re-crystallization
185 procedure on the physicochemical properties of LOR. In the first method the physical mixture
186 (PM) was prepared by Turbula mixer System (Schatz; Willy A. Bachofen AG
187 Maschinenfabrik, Basel, Switzerland) of LOR and PVP with 1:1 ratio at 50 rpm for 10 min

188 (PM). The second method involved the evaporative re-crystallization of the previously mixed
 189 PM which was dissolved in 100 mL ethanol. The solvent was evaporated at 25 °C. The
 190 preparation methods of the nanofibers and reference samples are summarized in Table 1.

191

Table 1. Composition and method of preparation of loratadine nanofibers and reference samples.

| Sample | Abbreviation | LOR (g) | PVP (g) | Method of preparation |
|--|---------------------|----------------|----------------|--|
| Raw loratadine | LOR | - | - | - |
| Physical mixture | PM (1:1) | 5 | 5 | Turbula mixer (for 10 mins) |
| Re-crystallized PM from 100 mL ethanol solution | SE (1:1) | 5 | 5 | Solvent evaporation (at 25 °C) |
| Loratadine-Nanofiber Experiment 1 | LOR-NF1 | 5 | 5 | Electrospinning method (<i>WD</i> = 65 mm) |
| Loratadine-Nanofiber Experiment 2 | LOR-NF2 | 5 | 5 | Electrospinning method (<i>WD</i> = 95 mm) |

192

193 **2.4 Scanning electron microscopy (SEM)**

194 The morphological appearance of the electrospun fibers was investigated by scanning electron
 195 microscopy (SEM) (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan) at 10 kV. The
 196 samples were coated with gold-palladium (90 seconds) by a sputter coater (Bio-Rad SC 502,
 197 VG Microtech, Uckfield, UK). One hundred nanofibers were selected from each SEM image,
 198 and the mean fiber diameter was measured by ImageJ 1.44p software (NIH, USA).

199

200 **2.5 Differential scanning calorimetry (DSC)**

201 Differential scanning calorimeter (Mettler Toledo TG 821e DSC; Mettler Inc.,
202 Schwerzenbach, Switzerland) was used to measure the thermal response of the samples.
203 Approximately 3 – 5 mg of the sample was precisely weighed into DSC sample pans, which
204 were hermetically sealed, then the lid was pierced. Each sample was measured in the
205 temperature interval of 25 °C – 300 °C at a heating rate of 5 °C min⁻¹ under constant argon
206 flow of 150 mL min⁻¹.

207

208 **2.6 Fourier-transform infrared spectroscopy (FT-IR)**

209 FTIR spectrum of each sample was obtained by using Fourier transform infrared spectroscopy
210 (Thermo Nicolet AVATAR 330, USA) equipped with GRAMS/AI Version 7.00 software.
211 The samples were ground with 150 mg dry KBr in a mortar and pestle, then compressed into a
212 disc at 10 t pressure. The discs were scanned 128 times at a resolution of 4 cm⁻¹ over
213 4000-400 cm⁻¹ wavenumber region.

214

215 **2.7 X-ray powder diffraction (XRPD)**

216 The crystalline phase of LOR, PM, SE, and LOR-NFs was characterized using an X-ray
217 powder diffraction (XRPD) BRUKER D8 Advance X-ray diffractometer (Bruker AXS
218 GmbH, Karlsruhe, Germany) with Cu K λ_1 radiation ($\lambda = 1.5406 \text{ \AA}$) and a VÅNTEC-1
219 detector. The powder samples were scanned at 40 kV and 40 mA, with an angular range 3° to
220 40° 2 θ , at a step time of 0.1 s and a step size of 0.02°r.

221 Eva software was used to separate the crystal and related amorphous peaks. Thus, the
222 software calculated the values of the integrated intensities of the amorphous and crystalline
223 contribution and the crystalline-only contribution. The crystallinity index values (X_c) of the
224 samples were calculated based on the following equation:

225

226 $X_c = A_{crystalline}/A_{crystalline} + A_{amorphous}$ (1)

227

228 **2.8 Dissolution studies**

229 Modified paddle method (USP dissolution apparatus, type II Pharma Test, Hainburg,
230 Germany) was used to determine the rates of dissolution of LOR, PM, SE, and LOR-NFs.
231 Samples containing 1.11 mg of loratadine were placed in 100 mL of phosphate buffer solution
232 at pH 7.4. The paddles were rotated at 100 rpm at 37 °C. At predetermined time 5 m aliquot
233 was withdrawn, filtered and measured for loratadine content using UV spectrophotometry
234 (Unicam UV/VIS Spectrophotometer, Cambridge, UK) at λ_{max} 248nm. The sampling was
235 performed for 120 min.

236

237 **2.9 Model-independent kinetics of dissolution profiles**

238 The dissolution behavior of the samples was characterized by calculating the dissolution
239 efficiency (DE) at different time points. The DE represents the percentage of the ratio of the
240 area up to time t divided by the area that described 100% dissolution at the same time (Khan,
241 1975):

242 $\%DE = (\int_0^t y \times dt) / (y_{100} \times t) \times 100\%$ (2)

243 The relative dissolution (RD) at 60 min was calculated relative to LOR by using the following
244 formula:

245 $RD_{60 \text{ min}} = \% DE_{60 \text{ min}} / \% DE_{60 \text{ min}}$ (3)

246

247 The area under the curve (AUC) was calculated by the trapezoidal method. AUC represents
248 the sum of all trapezia:

249 $AUC = \sum_{i=1}^{i=n} [(t_i - t_{i-1})(y_{i-1} + y_i) / 2]$ (4)

250 Where t_i represents the time point and y_i is the percentage of sample dissolved at time t_i . The
251 mean dissolution time (MDT) was calculated using the following formula (Costa, P., & Lobo,
252 2001)

$$253 \quad MDT = \frac{\sum_{i=1}^n t_{mid} \Delta M}{\sum_{i=1}^n \Delta M} \quad (5)$$

254 Where i is the dissolution sample number, n is the number of dissolution times, t_{mid} is the time
255 at the midpoint between times t_i and t_{i-1} , and ΔM is the amount of the dissolved drug (mg)
256 between times t_i and t_{i-1} .

257

258 **3. Results and discussion**

259 **3.1 Morphology and diameter of the LOR-NFs**

260 Smooth LOR nanofibers without the presence of beads were obtained from the
261 electrospinning of PVP alcohol solutions (Figure 2c and 2d). The collection distance had a
262 significant effect on the diameter of the prepared nanofibers. 95 mm collection distance
263 resulted in the formation of smooth nanofibers with small diameter (372 ± 181 nm). The low
264 diameter indicates that the nanofibers were stretched enough and sufficiently dried before
265 deposition on the collector. On the other hand, large diameter and fused fibers were obtained
266 at the shorter collection distance (65 mm). The nanofibers in this experiment (LOR-NF1)
267 appeared to not well featured and fused as an indication of the incomplete drying.
268 Furthermore, the protruded fiber shows a large diameter (948 ± 234 nm) and plasticized shape
269 as another indication of not complete drying. The PM showed the characteristic crystal of
270 LOR that showed a crystal size larger than $2 \mu\text{m}$ (Figure 2a). The SE showed irregular shapes
271 of LOR crystal, both short rod and prisms were present. Moreover, the rod shape crystals
272 exhibited a diameter of 562.7 ± 379 nm. The image of SE (Figure 2b) also showed the
273 aggregation and variety of distribution of LOR within the matrix of PVP polymer.

274

275 **Figure 2.** Scanning electron microscopy images of the (a) physical mixture; (b) sample
276 prepared by solvent evaporation; (c) electrospun nanofibers using the working distance of 65
277 mm (LOR-NF1); (d) electrospun nanofibers using the working distance of 95 mm (LOR-
278 NF2). The SEM image (d) shows separated, more uniform and smaller diameter nanofibers
279 compared to (c).

280

281 **3.2 Structural analysis (DSC, XRPD, and FT-IR)**

282 The DSC thermogram of LOR exhibited a sharp endothermic peak at 136.65 °C
283 corresponding to its melting point. The filament-forming matrix polymer PVP showed a broad
284 endotherm between 50 and 100 °C with a peak at 90 °C related to dehydration. The PM and
285 SE showed the characteristic peak of LOR indicating the presence of LOR in its crystalline
286 status. However, these endothermic peaks showed a lower intensity compared to pure LOR
287 due to the reduction of crystallinity either by the dilution effect (PM) and/or the preparation
288 method (SE). DSC of LOR-NFs exhibited a broad peak at temperatures lower than 60 °C,
289 primarily caused by the thermal effect of moisture evaporation and also the glass transition.
290 Moreover, the endothermic peak of LOR has disappeared in the prepared NFs indicating that
291 LOR was no longer present as a crystalline, but had been converted into an amorphous state
292 (Figure 3) (Akhgari et al., 2016).

293


294 **Figure 3.** DSC thermograms of the raw materials, reference samples and the prepared
295 nanofibers. The reference samples (PM and SE) show the melting point of LOR while
296 electrospun nanofibers represent the amorphous nature of the LOR.

297

298 The X-ray diffraction patterns of the LOR, PVP, PM, LOR-NF1, and LOR-NF2 are presented
299 in Figure 4. LOR showed numerous peaks between 3-30 of the 2- θ scale indicated that LOR is

300 present as a crystalline material. PVP showed two broad halo peaks specified to amorphous
301 status. PM showed the same characteristic peaks of pure LOR while SE showed the lower
302 intensity of LOR peaks in addition to the absence of many peaks due to the reduction of the
303 crystallinity. LOR-NF1 and LOR-NF2 showed complete disappearance of LOR characteristic
304 peaks. However, the two halo peaks of PVP were observed in the electrospun fibers at the
305 same position and showed the same shape.

306



307

308 **Figure 4.** XRPD diffractograms of the raw materials, reference samples and the prepared
 309 nanofibers. The electrospun nanofiber samples were amorphous, while the reference samples
 310 (PM and SE) show the crystalline peaks of LOR.

311
 312 The crystallinity index (X_C) values were calculated to reveal the changes in the degree of
 313 crystallinity of the LOR nanofibers and SE with respect to the PM (Gombás et al., 2002). The
 314 crystallinity indices from XRPD and DSC further suggest the amorphous state of the prepared
 315 LOR-NFs (Table 2). The nominal values of X_C obtained from DSC curves were different from
 316 that found by XRPD measurements for the samples. The differences in the measurements
 317 were expected because of using comparative methods to obtain data rather than absolute ones
 318 (Tserki et al., 2006). In the case of XRPD, the XRPD patterns were separated by the software
 319 into crystalline and amorphous peaks, and the degree of crystallinity was estimated based on
 320 equation (1). In spite of the qualitative analysis of the amorphous peaks by this method, the
 321 same procedure was applied to all samples in order to get comparable values. On the other
 322 hand, the values obtained by DSC were based on the heat of fusion. Both methods represented
 323 the variation of crystallinity between the prepared samples.

324

Table 2. The calculated crystallinity index (X_C) of the reference samples and the prepared nanofibers after DSC and XRPD measurements compared to LOR.

| Sample | Crystallinity index (%) | |
|---------|-------------------------|-------|
| | XRPD | DSC |
| SE | 32.71 | 47.29 |
| LOR-NF1 | 30.28 | 0.93 |
| LOR-NF2 | 9.79 | 0.93 |

325

326 FT-IR analysis was performed to check the **compatibility and** interactions between LOR and
327 the **nanofiber** matrix (Figure 5). The FTIR bands that are characteristic to LOR are located at
328 997 cm^{-1} for aryl C-Cl stretching and $1,227\text{ cm}^{-1}$ for -C-N stretching of aryl N. In addition to
329 bands at 1560 and 1703 cm^{-1} corresponded to C-O bonds of the amide or ester groups. Bands
330 from 3000 to 2850 cm^{-1} correspond to the C-H bond (Alshweiat et al., 2018). On the other
331 hand, PVP showed its characteristic bands at 3448.3 cm^{-1} due to O-H stretching vibrations,
332 2924.4 cm^{-1} related to asymmetric stretching of CH_2 , 1652.3 cm^{-1} for C=O stretching and a
333 broad peak at 1289.4 cm^{-1} due to C-N stretching vibrations (Sriyanti et al., 2018). **The FTIR**
334 **spectra of the physical mixture and the reference sample showed no obvious shift of the peaks**
335 **of the functional groups corresponding for hydrogen bonding. However, LOR-NF samples**
336 **showed shifted peaks of LOR and PVP. The main effects were observed in the O-H and C=O**
337 **regions. The hydroxyl peak of PVP at 3448.3 cm^{-1} shifted to 3512 cm^{-1} and the C=O**
338 **stretching peaks at 1652.3 cm^{-1} shifted to 1666.5 cm^{-1} . The band of LOR shifted from 1702.8**
339 **to 1666.5 overlapping with the shifted peak of PVP. The peak shift of carbonyl stretching was**
340 **thought to be a result of hydrogen bond intermolecular interaction between LOR and PVP**
341 **(Zhao et al., 2017). Since the FTIR results showed only hydrogen bonding, but no covalent**
342 **bonding, LOR and PVP as nanofibers are indicated to be compatible with each other (Frizon**
343 **et al., 2013; John et al., 2002).**

344

345 **Figure 5.** FT-IR spectra of the raw materials, reference samples and the prepared electrospun
346 nanofibers. The electrospun nanofiber samples and SE sample show an intermolecular
347 interaction between LOR and PVP via hydrogen bond formation.

348

349 According to the aforementioned characteristics of the LOR-NFs, only the LOR-NF2 showed
350 the complete separation of the fibers and nanofibers with small diameters. Therefore, it was
351 selected for further solubility and dissolution studies.

352

353 **3.3 Solubility and Dissolution studies**

354 LOR-NF2 showed a 26.2-fold increase of LOR solubility compared to the pure drug in
355 phosphate buffer solution, pH 7.4. The solubility of LOR-NF2 was $13.1 \pm 0.26 \mu\text{g mL}^{-1}$
356 compared to $0.50 \pm 0.11 \mu\text{g mL}^{-1}$ for LOR at 25 °C (Table 3). The dissolution behaviors of the
357 samples are shown in Figure 6. LOR-NF2 showed the highest release rate, more than 66% of
358 the drug was released in the first 10 min compared to less than 0.5% of the pure LOR. SE
359 samples also showed higher dissolution than LOR because of their contact with the
360 hydrophilic polymer. However, the PM exhibited a release behavior similar to LOR. The
361 improvement in the dissolution of LOR from the electrospun fibers was attributed to the
362 presence of LOR in the amorphous state. Loratadine has been reported to **have** higher kinetic
363 energy in the amorphous state, hence higher dissolution than its crystalline state. Moreover,
364 the three-dimensional structure of the electrospun fiber can offer a larger surface area,
365 therefore, water can diffuse more efficiently into the polymer to dissolve the drug. The
366 dissolution efficiency of LOR-NF2 was enhanced at all selected time points, as well as RD
367 value. The mean dissolution time of LOR-NF2 was decreased. These results confirmed that
368 the dissolution became fast due to the amorphous state of the drug in the nanofibers, presence
369 of the additives, and reduction of the particle size Table (4).

370

Table 3. Solubility ($\mu\text{g mL}^{-1}$) of LOR and the prepared samples in phosphate buffer at pH 7.4 at a temperature of 25 °C.

| Sample | Solubility ($\mu\text{g mL}^{-1}$) |
|--------|--------------------------------------|
|--------|--------------------------------------|

| | |
|---------|-----------------|
| LOR | 0.50 ± 0.11 |
| PM | 6.45 ± 0.06 |
| SE | 7.58 ± 0.38 |
| LOR-NF2 | 13.1 ± 0.11 |

371
372 **Figure 6.** Dissolution behavior of LOR, reference samples and the prepared electrospun
373 nanofiber with working distance 6.5 mm in phosphate buffer solution, pH 7.4. The nanofiber-
374 based sample has improved dissolution kinetics and higher dissolution rates than the raw LOR
375 or the reference samples (PM and SE).

Table 4. Dissolution efficiency (DE) at different time points, mean dissolution time (MDT), and relative dissolution (RD), with respect to the raw LOR at 60 min of the samples.

| Sample | %DE ₃₀ | %DE ₆₀ | %DE ₁₂₀ | MDT | RD ₆₀ |
|---------|-------------------|-------------------|--------------------|-------|------------------|
| LOR | 1.47 | 3.73 | 4.60 | 36.69 | - |
| PM | 0.69 | 1.46 | 3.45 | 53.63 | 0.39 |
| SE | 5.64 | 7.06 | 8.54 | 13.28 | 1.89 |
| LOR-NF2 | 61.2 | 70.89 | 75.52 | 5.87 | 19.0 |

376
377 **4. Conclusion**
378 This study demonstrated home setup, low-cost, 3D-printed, electrospinning sources for
379 generation of nanofibers using a rotating metal drum as a collector. Nanofibers of LOR were
380 prepared in the hydrophilic PVP polymer and compared to the corresponding physical
381 mixture and conventional reference sample, that was prepared by the solvent evaporation
382 method. The distance between the nozzle and collecting drum was an influential process-
383 parameter; it affected the possibility of preparing separated nanofibers. Moreover, it affected
384 the diameters of the nanofibers. 65 mm distance was optimum to produce separated
385 nanofibers with diameters of 372 nm. The prepared nanofibers displayed an amorphous status
386 of LOR, and the spectroscopic studies indicated interactions between the drug and polymer.
387 As a result of the formation of the amorphous nanofibers, the solubility and dissolution of

388 LOR were enhanced. Solubility studies showed a marked increase in release rate compared to
389 the pure drug. LOR-NF2 showed a 26.2-fold increase in the solubility of LOR as compared to
390 the pure drug in phosphate buffer solution, pH 7.4. Moreover, more than 66% of the drug was
391 released in the first 10 min compared to less than 4% drug release from the conventional
392 reference sample (SE). Therefore, faster and higher dissolution was achieved for the poorly
393 water-soluble LOR by fabrication of electrospun nanofibers. **The improved dissolution could**
394 **enable the designing of new alternative loratadine formulations, including buccal,**
395 **transdermal, and topical dosage forms.**
396

397 **Declaration of interests**

398 The authors declare no conflicts of interests.

399

400 **Authors' contributions**

401 AR designed the experiment and managed the analysis. AA carried out the analysis,
402 interpreted the results, and wrote the manuscript. CI helped in interpreting of the results. GO
403 and AE performed the electrospinning experiments. NR came up with the experimental design
404 and supervised the overall project.

405

406 **Acknowledgements**

407 The authors would like to thank Jing Huang of The University of Edinburgh for her assistance
408 with the preparation for the experiments. We thank Michel Vong, and Yunxi Gao for their
409 feedback on the paper. We would also like to thank Fergus Dingwall for his appreciated
410 laboratory assistance. The authors acknowledge the Ministry of Human Capacities, Hungary,
411 grant number 20391-3/2018/FEKUSTRAT, for funding.

412

413 **References**

414 Akhgari, A., Dezfuli, A.G., Rezaei, M., Kiarsi, M., Abbaspour, M., 2016. The design and
415 evaluation of a fast-dissolving drug delivery system for loratadine using the
416 electrospinning method. Jundishapur J. Nat. Pharm. Prod. 11.

417 <https://doi.org/10.17795/jjnpp-33613>

418 Alshweiat, A., Katona, G., Csóka, I., Ambrus, R., 2018. Design and characterization of
419 loratadine nanosuspension prepared by ultrasonic-assisted precipitation. *Eur. J. Pharm.*
420 *Sci.* <https://doi.org/10.1016/j.ejps.2018.06.010>

421 Ambrus, R., Radacsi, N., Szunyogh, T., van der Heijden, A.E.M., ter Horst, J.H., Szabó-
422 Révész, P., 2013. Analysis of submicron-sized niflumic acid crystals prepared by
423 electrospray crystallization. *J. Pharm. Biomed. Anal.* 76, 1–7.
424 <https://doi.org/10.1016/j.jpba.2012.12.001>

425 Amidon, G.L., Lennernäs, H., Shah, V.P., Crison, J.R., 1995. A Theoretical Basis for a
426 Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product
427 Dissolution and in Vivo Bioavailability. *Pharm. Res.* 12, 413–420.
428 <https://doi.org/10.1023/A:1016212804288>

429 Arya, A., Sharma, V., Pathak, K., 2012. Pharmaceutical evaluation and dynamic vapor
430 sorption studies of fast dissolving intraoral films of Loratadine. *Pharm. Dev. Technol.*
431 7450, 1–10. <https://doi.org/10.3109/10837450.2012.685659>

432 Badawy, S.I.F., Ghorab, M.M., Adeyeye, C.M., 1996. Characterization and bioavailability of
433 danazol-hydroxypropyl β -cyclodextrin coprecipitates. *Int. J. Pharm.* 128 128, 45–54.

434 Baskakova, A., Awwad, S., Gill, H., Khaw, P.T., Brocchini, S., Zhilyakova, E., Williams,
435 G.R., Hospital, M.E., 2016. Electrospun formulations of acyclovir , ciprofloxacin and
436 cyanocobalamin for ocular drug delivery. *Int. J. Pharm.* 502, 208–228.

437 Brewster, M.E., Verreck, G., Chun, I., Rosenblatt, J., Mensch, J., Dijck, A. Van, Noppe, M.,
438 Arie, A., 2004. The use of polymer-based electrospun nanofibers containing amorphous
439 drug dispersions for the delivery of poorly water-soluble pharmaceuticals.

440 Chuangchote, S., Sagawa, T., Yoshikawa, S., 2009. Electrospinning of Poly (vinyl
441 pyrrolidone): Effects of Solvents on Electrospinnability for the Fabrication of Poly (p -

442 phenylene vinylene) and TiO₂ Nanofibers. *J. Appl. Polym. Sci.* 114, 2777–2791.
443 <https://doi.org/DOI 10.1002/app.30637>

444 Costa, P., & Lobo, J.M.S., 2001. Modelling and Comparison of Dissolution Profiles. *Eur. J.*
445 *Pharm. Sci.* 13, 123–133. [https://doi.org/10.1016/S0928-0987\(01\)00095-1](https://doi.org/10.1016/S0928-0987(01)00095-1)

446 Craig, D.Q.M., 2002. The mechanisms of drug release from solid dispersions in water-soluble
447 polymers. *Int. J. Pharm.* [https://doi.org/10.1016/S0378-5173\(01\)00891-2](https://doi.org/10.1016/S0378-5173(01)00891-2)

448 Dagenais, C., Avdeef, A., Tsinman, O., Dudley, A., Beliveau, R., 2009. P-glycoprotein
449 deficient mouse in situ blood-brain barrier permeability and its prediction using an in
450 combo PAMPA model. *Eur. J. Pharm. Sci.* 38, 121–137.
451 <https://doi.org/10.1016/j.ejps.2009.06.009>

452 Fong, H., Chun, I., Reneker, D.H., 1999. Beaded nanofibers formed during electrospinning.
453 *Polym.* 40 1585–4592.

454 Frizon, F., Eloy, J. de O., Donaduzzi, C.M., Mitsui, M.L., Marchetti, J.M., 2013. Dissolution
455 rate enhancement of loratadine in polyvinylpyrrolidone K-30 solid dispersions by solvent
456 methods. *Powder Technol.* 235, 532–539. <https://doi.org/10.1016/j.powtec.2012.10.019>

457 Gombás, Á., Szabó-Révész, P., Kata, M., Regdon, G., Eros, I., 2002. Quantitative
458 determination of crystallinity of α -lactose monohydrate by DSC. *J. Therm. Anal.*
459 *Calorim.* 68, 503–510. <https://doi.org/10.1023/A:1016039819247>

460 Han, M.Z.I.K., Aus, D.R., Filipovi, P., 2004. Classification of Loratadine Based on the
461 Biopharmaceutics Drug Classification Concept and Possible in Vitro – in Vivo
462 Correlation. *Biol. Pharm. Bull.* 27, 1630–1635. <https://doi.org/10.1248/bpb.27.1630>

463 Huang, J., Radacsi, N., 2019. Low-cost FDM 3D-printed modular
464 electro spray/electrospinning setup for biomedical applications. *3D Print. Med.*
465 Submitted, 2019.

466 Huang, Z.M., Zhang, Y.Z., Kotaki, M., Ramakrishna, S., 2003. A review on polymer

467 nanofibers by electrospinning and their applications in nanocomposites. *Compos. Sci.*
468 *Technol.* 63, 2223–2253. [https://doi.org/10.1016/S0266-3538\(03\)00178-7](https://doi.org/10.1016/S0266-3538(03)00178-7)

469 Jiang, H., Fang, D., Hsiao, B., Chu, B., Chen, W., 2004. Preparation and characterization of
470 ibuprofen-loaded poly(lactide-co-glycolide)/poly(ethylene glycol)-g-chitosan electrospun
471 membranes. *J. Biomater. Sci. Polym. Ed.* 15, 279–296.

472 John, J., Mani, R., Bhattacharya, M., 2002. Evaluation of compatibility and properties of
473 biodegradable polyester blends. *J. Polym. Sci. Part A Polym. Chem.* 40, 2003–2014.
474 <https://doi.org/10.1002/pola.10297>

475 Khan, K.A., 1975. The concept of dissolution efficiency. *J. Pharm. Pharmacol.* 27, 48–49.
476 <https://doi.org/10.1111/j.2042-7158.1975.tb09378.x>

477 Li, D., Xia, Y., 2003. Fabrication of Titania Nanofibers by Electrospinning. *Nano Lett.* 3,
478 554–560.

479 Li, H., Tan, Y., Yang, L., Gao, L., Wang, T., Yang, X., Quan, D., 2015. Dissolution
480 evaluation in vitro and bioavailability in vivo of self-microemulsifying drug delivery
481 systems for pH-sensitive drug loratadine. *J. Microencapsul.* 32, 175–180.
482 <https://doi.org/10.3109/02652048.2014.985340>

483 Li, X., Kanjwal, M.A., Lin, L., Chronakis, I.S., 2013. Electrospun polyvinyl-alcohol
484 nanofibers as oral fast-dissolving delivery system of caffeine and riboflavin. *Colloids*
485 *Surfaces B Biointerfaces* 103, 182–188. <https://doi.org/10.1016/j.colsurfb.2012.10.016>

486 Nacsá, Á., Ambrus, R., Berkesi, O., Szabó-Révész, P., Aigner, Z., 2008. Water-soluble
487 loratadine inclusion complex: Analytical control of the preparation by microwave
488 irradiation. *J. Pharm. Biomed. Anal.* 48, 1020–1023.
489 <https://doi.org/10.1016/j.jpba.2008.07.001>

490 Nacsá, Á., Berkesi, O., Szabó-Révész, P., Aigner, Z., 2009. Achievement of pH-independence
491 of poorly-soluble, ionizable loratadine by inclusion complex formation with dimethyl-β-

492 cyclodextrin. *J. Incl. Phenom. Macrocycl. Chem.* 64, 249–254.
493 <https://doi.org/10.1007/s10847-009-9558-1>

494 Nagy, Z.K., Balogh, A., Démuth, B., Pataki, H., Vigh, T., Szabó, B., Molnár, K., Schmidt,
495 B.T., Horák, P., Marosi, G., Verreck, G., Van Assche, I., Brewster, M.E., 2015. High
496 speed electrospinning for scaled-up production of amorphous solid dispersion of
497 itraconazole. *Int. J. Pharm.* 480, 137–142. <https://doi.org/10.1016/j.ijpharm.2015.01.025>

498 Nagy, Z.K., Balogh, A., Vajna, B., Farkas, A., Patyi, G., Kramarics, Á., Marosi, G., 2012.
499 Comparison of Electrospun and Extruded Soluplus®-Based Solid Dosage Forms of
500 Improved Dissolution. *J. Pharm. Sci.* 101, 322–332. <https://doi.org/10.1002/jps.22731>

501 Nuansing, W., Ninmuang, S., Jarernboon, W., Maensiri, S., Seraphin, S., 2006. Structural
502 characterization and morphology of electrospun TiO₂nanofibers. *Mater. Sci. Eng. B*
503 *Solid-State Mater. Adv. Technol.* 131, 147–155.
504 <https://doi.org/10.1016/j.mseb.2006.04.030>

505 Omar, L., El-Barghouthi, M.I., Masoud, N.A., Abdoh, A.A., Al Omari, M.M., Zughul, M.B.,
506 Badwan, A.A., 2007. Inclusion complexation of loratadine with natural and modified
507 cyclodextrins: Phase solubility and thermodynamic studies. *J. Solution Chem.* 36, 605–
508 616. <https://doi.org/10.1007/s10953-007-9136-3>

509 Paaver, U., Laidmäe, I., Santos, H.A., Yliruusi, J., 2016. Development of a novel electrospun
510 nanofibrous delivery system for poorly water-soluble β -sitosterol. *Asian J. Pharm. Sci.*
511 11, 500–506. <https://doi.org/10.1016/j.ajps.2016.04.005>

512 Potrč, T., Baumgartner, S., Roškar, R., Planinšek, O., Lavrič, Z., Kristl, J., Kocbek, P., 2015.
513 Electrospun polycaprolactone nanofibers as a potential oromucosal delivery system for
514 poorly water-soluble drugs. *Eur. J. Pharm. Sci.* 75, 101–113.
515 <https://doi.org/10.1016/j.ejps.2015.04.004>

516 Radacsi, N., Campos, F.D., Chisholm, C.R.I., Giapis, K.P., 2018. Spontaneous formation of

517 nanoparticles on electrospun nanofibres. *Nat. Commun.* 9, 3–10.
518 <https://doi.org/10.1038/s41467-018-07243-5>

519 Radacsi, N., Giapis, K.P., Ovari, G., Szabó-Révész, P., Ambrus, R., 2019. Electrospun
520 nanofiber-based niflumic acid capsules with superior physicochemical properties. *J.*
521 *Pharm. Biomed. Anal.* 166, 371–378. <https://doi.org/10.1016/j.jpba.2019.01.037>

522 Rodriguez Amado, J.R., Prada, A.L., Duarte, J.L., Keita, H., da Silva, H.R., Ferreira, A.M.,
523 Sosa, E.H., Carvalho, J.C.T., 2017. Development, stability and in vitro delivery profile of
524 new loratadine-loaded nanoparticles. *Saudi Pharm. J.* 25, 1158–1168.
525 <https://doi.org/10.1016/j.jsps.2017.07.008>

526 Ryu, Y.J., Kim, H.Y., Lee, K.H., Park, H.C., Lee, D.R., 2003. Transport properties of
527 electrospun nylon 6 nonwoven mats. *Eur. Polym. J.* 39, 1883–1889.
528 [https://doi.org/10.1016/S0014-3057\(03\)00096-X](https://doi.org/10.1016/S0014-3057(03)00096-X)

529 Shahriar, S., Mondal, J., Hasan, M., Revuri, V., Lee, D., Lee, Y.-K., 2019. Electrospinning
530 Nanofibers for Therapeutics Delivery. *Nanomaterials* 9, 532.
531 <https://doi.org/10.3390/nano9040532>

532 Simons, F.E.R., 2002. Comparative pharmacology of H1 antihistamines: clinical relevance.
533 *Am. J. Med.* 113 Suppl, 38S–46S. [https://doi.org/10.1016/S0002-9343\(02\)01436-5](https://doi.org/10.1016/S0002-9343(02)01436-5)

534 Sriyanti, I., Edikresnha, D., Rahma, A., Munir, M.M., Rachmawati, H., Khairurrijal, K., 2018.
535 Mangosteen pericarp extract embedded in electrospun PVP nanofiber mats:
536 Physicochemical properties and release mechanism of α -mangostin. *Int. J. Nanomedicine*
537 13, 4927–4941. <https://doi.org/10.2147/IJN.S167670>

538 Tserki, V., Matzinos, P., Pavlidou, E., Vachliotis, D., Panayiotou, C., 2006. Biodegradable
539 aliphatic polyesters . Part I . Properties and biodegradation of poly (butylene succinate-
540 co -butylene adipate) 91. <https://doi.org/10.1016/j.polymdegradstab.2005.04.035>

541 Verreck, G., Chun, I., Peeters, J., Rosenblatt, J., Brewster, M.E., 2003. Preparation and

542 characterization of nanofibers containing amorphous drug dispersions generated by
543 electrostatic spinning. *Pharm. Res.* 20, 810–817.
544 <https://doi.org/10.1023/A:1023450006281>

545 Yang, Q., Zhenyu, L.I., Hong, Y., Zhao, Y., Qiu, S., Wang, C.E., Wei, Y., 2004. Influence of
546 solvents on the formation of ultrathin uniform poly(vinyl pyrrolidone) nanofibers with
547 electrospinning. *J. Polym. Sci. Part B Polym. Phys.* 42, 3721–3726.
548 <https://doi.org/10.1002/polb.20222>

549 Yu, D., Branford-White, C., White, K., Li, X.-L., Zhu, L.-M., 2010. Dissolution Improvement
550 of Electrospun Nanofiber-Based Solid Dispersions for Acetaminophen. *AAPS*
551 *PharmSciTech* 11, 809–817. <https://doi.org/10.1208/s12249-010-9438-4>

552 Yu, D.G., Branford-White, C., Shen, X.X., Zhang, X.F., Zhu, L.M., 2010. Solid dispersions
553 of ketoprofen in drug-loaded electrospun nanofibers. *J. Dispers. Sci. Technol.* 31, 902–
554 908. <https://doi.org/10.1080/01932690903223948>

555 Zhao, Y., Song, X., Sun, J., He, Z., Sun, M., Zhang, S., Wang, J., 2017. Molecular mechanism
556 of polymer-assisting supersaturation of poorly water-soluble loratadine based on
557 experimental observations and molecular dynamic simulations. *Drug Deliv. Transl. Res.*
558 7, 738–749. <https://doi.org/10.1007/s13346-017-0401-8>

559